<DOC>
	<DOC>NCT00423657</DOC>
	<brief_summary>The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of complicated skin infections in adults.</brief_summary>
	<brief_title>Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections</brief_title>
	<detailed_description>Additional purpose of this study is to compare ceftaroline effectivity versus Vancomycin plus Aztreonam in the treatment of complicated skin infections in adults.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Skin Diseases, Infectious</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<mesh_term>Aztreonam</mesh_term>
	<criteria>Skin and skin structure infection (SSSI) that involves deeper soft tissue or requires significant surgical intervention, or cellulitis or abscess on lower extremity which occurs in subjects with diabetes mellitus or welldocumented peripheral vascular disease. Prior treatment of current complicated skin and skin structure infection (cSSSI) with an antimicrobial. Failure of vancomycin or aztreonam as therapy for the current cSSSI, or prior isolation of an organism with in vitro resistance to vancomycin or aztreonam.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Abscess</keyword>
	<keyword>Antibacterial</keyword>
	<keyword>Antibiotic</keyword>
	<keyword>Antimicrobial</keyword>
	<keyword>Bacterial infection, skin</keyword>
	<keyword>Ceftaroline</keyword>
	<keyword>Ceftaroline acetate</keyword>
	<keyword>Cellulitis</keyword>
	<keyword>Cephalosporin</keyword>
	<keyword>Complicated skin and skin structure infection (cSSSI)</keyword>
	<keyword>cSSSI</keyword>
	<keyword>Intravenous</keyword>
	<keyword>Methicillin-resistant Staphylococcus Aureus (MRSA)</keyword>
	<keyword>PPI-0903</keyword>
	<keyword>Prodrug</keyword>
	<keyword>Skin disease, bacterial</keyword>
	<keyword>Skin infection</keyword>
	<keyword>Staphylococcal skin infection</keyword>
	<keyword>Staphylococcus aureus</keyword>
	<keyword>Streptococcal skin infection</keyword>
	<keyword>Surgical site infection</keyword>
	<keyword>TAK-599</keyword>
</DOC>